About heartsciences inc - HSCS
HeartSciences, Inc. is a medical technology company, which focuses on applying innovative AI-based technology to an electrocardiogram (ECG) to expand and improve an ECG's clinical usefulness. Its objective is to make an ECG a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. The firm offers MyoVista, a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction. The company was founded on August 16, 2007 and is headquartered in Southlake, TX.
HSCS At a Glance
HeartSciences, Inc.
550 Reserve Street
Southlake, Texas 76092
| Phone | 1-682-237-7781 | Revenue | 4.32K | |
| Industry | Medical Specialties | Net Income | -9,141,875.00 | |
| Sector | Health Technology | Employees | 14 | |
| Fiscal Year-end | 04 / 2027 | |||
| View SEC Filings |
HSCS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1,185.36 |
| Price to Book Ratio | 27.617 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.894 |
| Enterprise Value to Sales | 1,713.433 |
| Total Debt to Enterprise Value | 0.532 |
HSCS Efficiency
| Revenue/Employee | 308.50 |
| Income Per Employee | -652,991.071 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.001 |
HSCS Liquidity
| Current Ratio | 0.501 |
| Quick Ratio | 0.366 |
| Cash Ratio | 0.341 |
HSCS Profitability
| Gross Margin | -2,982.149 |
| Operating Margin | -194,787.451 |
| Pretax Margin | -211,666.474 |
| Net Margin | -211,666.474 |
| Return on Assets | -192.753 |
| Return on Equity | -4,239.897 |
| Return on Total Capital | -219.614 |
| Return on Invested Capital | -1,984.648 |
HSCS Capital Structure
| Total Debt to Total Equity | 1,741.417 |
| Total Debt to Total Capital | 94.569 |
| Total Debt to Total Assets | 74.803 |
| Long-Term Debt to Equity | 77.95 |
| Long-Term Debt to Total Capital | 4.216 |